Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
CD28
CD40
CTLA-4
PD-1
TIL
dendritic cell
exhaustion
myeloid niche
ovarian
tumor
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
13 12 2021
13 12 2021
Historique:
received:
02
12
2020
revised:
06
07
2021
accepted:
15
10
2021
pubmed:
6
11
2021
medline:
5
1
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that tumor-specific CD8
Identifiants
pubmed: 34739845
pii: S1535-6108(21)00559-6
doi: 10.1016/j.ccell.2021.10.008
pmc: PMC8861565
mid: NIHMS1756294
pii:
doi:
Substances chimiques
CD28 Antigens
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1642.e20Subventions
Organisme : NCI NIH HHS
ID : R01 CA098951
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA116779
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA083638
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB026892
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA225088
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests G.C. has received grants from Celgene, Boehringer-Ingelheim, BMS, and Tigen, and participated in advisory board or presented at Roche, MSD Merck, BMS, AstraZeneca, and Geneos Tx-sponsored symposia (fees received by G.C.’s institution). G.C. has patents in the domain of antibodies, vaccines, T cell expansion, and engineering technologies, and receives royalties from UPenn. P.K.S. is a member of the SAB or Board of Directors of Applied Biomath, Glencoe Software, RareCyte Inc., and has equities in these companies; he is a member of the SAB of NanoString Inc. and a consultant for Merck and Montai Health. P.K.S. has received research funding from Novartis and Merck. D.J.P. receives research funding from Incyte and serves as an adviser, receives fees, stock options, and research funding from InsTIL Bio. R.G. holds a patent for TCR sequencing. J.D. is presently a US FDA employee. R.T., C.N., V.A., and M.A.D. are current employees of Ichnos Sciences Biotherapeutics SA. None of the above declared relationships has influenced the content of this manuscript. The other authors declare no competing financial interests.
Références
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Immunity. 2020 May 19;52(5):724-726
pubmed: 32433943
Clin Cancer Res. 2012 Mar 1;18(5):1374-85
pubmed: 22241791
Cell Rep. 2020 Jun 30;31(13):107820
pubmed: 32610123
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802
pubmed: 22454499
Cancer Immunol Res. 2019 Jun;7(6):963-976
pubmed: 31064777
Cell Rep. 2021 Jul 20;36(3):109412
pubmed: 34289354
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016-21
pubmed: 18809920
J Biol Chem. 2011 Dec 2;286(48):41723-41735
pubmed: 21990358
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Elife. 2018 Jul 11;7:
pubmed: 29993362
J Immunol. 2013 Feb 1;190(3):940-7
pubmed: 23269245
Cancer Res. 2006 May 15;66(10):5452-60
pubmed: 16707474
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Cancer Biol Ther. 2006 Jun;5(6):635-42
pubmed: 16627987
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57
pubmed: 18279065
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Cancer Cell. 2009 Dec 8;16(6):521-32
pubmed: 19962670
PLoS Biol. 2011 Sep;9(9):e1001149
pubmed: 21931534
Immunity. 2019 Nov 19;51(5):840-855.e5
pubmed: 31606264
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
Genome Med. 2020 Feb 28;12(1):22
pubmed: 32111241
J Proteome Res. 2015 Aug 7;14(8):3322-35
pubmed: 26088811
Nucleic Acids Res. 2015 Jul 1;43(W1):W57-64
pubmed: 25925574
Cancer Gene Ther. 2014 Mar;21(3):95-102
pubmed: 24481488
PLoS Pathog. 2013 Mar;9(3):e1003208
pubmed: 23516358
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Viral Immunol. 2008 Dec;21(4):435-42
pubmed: 19115932
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W382-8
pubmed: 15980494
J Cell Biol. 2020 Jun 1;219(6):
pubmed: 32437509
Cancer Immunol Res. 2019 Sep;7(9):1412-1425
pubmed: 31337659
Clin Cancer Res. 2017 Jun 15;23(12):3168-3180
pubmed: 28193624
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161104
Sci Rep. 2017 Dec 4;7(1):16827
pubmed: 29203787
Blood. 2013 Jun 13;121(24):4894-901
pubmed: 23641014
Nat Cancer. 2020 Jan;1(1):86-98
pubmed: 35121834
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Eur J Immunol. 2001 Feb;31(2):459-66
pubmed: 11180110
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nature. 2020 Aug;584(7822):624-629
pubmed: 32788723
Front Immunol. 2019 Mar 29;10:630
pubmed: 31001256
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
Nat Immunol. 2014 Apr;15(4):373-83
pubmed: 24584090
J Exp Med. 2016 Aug 22;213(9):1819-34
pubmed: 27455951
J Biol Chem. 1996 Oct 25;271(43):26762-71
pubmed: 8900156
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
F1000Res. 2017 May 26;6:748
pubmed: 28663787
J Mol Diagn. 2001 Aug;3(3):105-10
pubmed: 11486049
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Sci Adv. 2021 Feb 26;7(9):
pubmed: 33637530
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
J Immunol. 2003 Aug 1;171(3):1588-95
pubmed: 12874253
PLoS One. 2011;6(7):e22845
pubmed: 21829534
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
PLoS One. 2012;7(2):e30269
pubmed: 22348002
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618661
Hum Immunol. 2004 Apr;65(4):282-90
pubmed: 15120183
J Immunol. 1999 Dec 15;163(12):6622-30
pubmed: 10586057
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
Nat Med. 2020 Aug;26(8):1271-1279
pubmed: 32572264
Nature. 2001 Mar 29;410(6828):604-8
pubmed: 11279501
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Immunity. 2010 Jan 29;32(1):67-78
pubmed: 20060330
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Sci Adv. 2019 Jul 17;5(7):eaav9732
pubmed: 31328159
Cancer Immunol Immunother. 2009 May;58(5):759-67
pubmed: 18836716
Am J Pathol. 1999 Jan;154(1):61-6
pubmed: 9916919
PLoS One. 2010 Sep 28;5(9):
pubmed: 20927193
PLoS Med. 2009 Feb 3;6(2):e24
pubmed: 19192944
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2480-9
pubmed: 23610399
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Cancer Immunol Immunother. 2012 May;61(5):629-41
pubmed: 22021066
Gene Ther. 2007 Jun;14(12):921-9
pubmed: 17377599
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Sci. 2012 Jul;103(7):1334-41
pubmed: 22497737
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Cell. 2019 Jan 10;176(1-2):404
pubmed: 30633907
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817208
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
Nature. 2017 Dec 14;552(7684):253-257
pubmed: 29211713
Sci Immunol. 2018 Nov 2;3(29):
pubmed: 30389797
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell Rep. 2017 Dec 12;21(11):3190-3204
pubmed: 29241546
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251903
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Database (Oxford). 2013 Apr 02;2013:bat013
pubmed: 23550061
J Immunol. 2006 Mar 1;176(5):2730-8
pubmed: 16493028
PLoS One. 2012;7(2):e30550
pubmed: 22348014
J Transl Med. 2017 Apr 20;15(1):79
pubmed: 28427434
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Nat Commun. 2017 Jun 08;8:14836
pubmed: 28594001
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Nat Cancer. 2020 Jul;1(7):681-691
pubmed: 35122038
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42
pubmed: 17652518
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
J Clin Invest. 2016 Sep 1;126(9):3447-52
pubmed: 27525433
Nucleic Acids Res. 2012 Aug;40(15):e114
pubmed: 22718975
J Immunol. 2004 Jun 1;172(11):6803-9
pubmed: 15153498
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
PLoS One. 2010 Mar 12;5(3):e9615
pubmed: 20300634
Nat Methods. 2017 Sep;14(9):873-876
pubmed: 28783155
J Immunol. 2001 Jun 1;166(11):6509-13
pubmed: 11359801
J Immunol. 2008 Feb 15;180(4):2158-64
pubmed: 18250422
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
J Biol Chem. 2005 Jan 14;280(2):1037-43
pubmed: 15522880
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
Cell Metab. 2019 Jan 8;29(1):156-173.e10
pubmed: 30244973
FEBS Lett. 2004 Sep 10;574(1-3):37-41
pubmed: 15358536
Immunity. 2004 Sep;21(3):401-13
pubmed: 15357951
Cancer Cell. 2020 Nov 9;38(5):685-700.e8
pubmed: 33007259
PLoS One. 2014 Feb 24;9(2):e89263
pubmed: 24586641